Incyte Corporation (NASDAQ:INCY) – Analysts at William Blair lowered their Q4 2017 earnings per share estimates for shares of Incyte Corporation in a research report issued to clients and investors on Wednesday. William Blair analyst Y. Xu now forecasts that the biopharmaceutical company will post earnings per share of ($0.59) for the quarter, down from their previous estimate of $0.04. William Blair also issued estimates for Incyte Corporation’s Q1 2018 earnings at ($0.21) EPS, Q2 2018 earnings at ($0.06) EPS, Q3 2018 earnings at $0.47 EPS, FY2018 earnings at $0.30 EPS and FY2019 earnings at $1.02 EPS.
Several other research analysts have also commented on the company. Oppenheimer Holdings, Inc. set a $135.00 target price on Incyte Corporation and gave the stock a “hold” rating in a research report on Tuesday, October 31st. BMO Capital Markets boosted their price objective on Incyte Corporation from $162.00 to $166.00 and gave the company an “outperform” rating in a research report on Tuesday, October 31st. J P Morgan Chase & Co restated a “buy” rating on shares of Incyte Corporation in a research report on Tuesday, October 31st. Goldman Sachs Group, Inc. (The) assumed coverage on Incyte Corporation in a research report on Friday, October 6th. They set a “buy” rating and a $160.00 price objective for the company. Finally, Jefferies Group LLC restated a “buy” rating on shares of Incyte Corporation in a research report on Friday, October 6th. Seven equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $144.98.
TRADEMARK VIOLATION WARNING: This article was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.com-unik.info/2017/11/06/incyte-corporation-to-post-q4-2017-earnings-of-0-59-per-share-william-blair-forecasts-incy.html.
Incyte Corporation (NASDAQ:INCY) opened at $105.08 on Monday. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01. Incyte Corporation has a 12-month low of $83.01 and a 12-month high of $153.15.
Incyte Corporation (NASDAQ:INCY) last issued its earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The business’s revenue was up 41.6% on a year-over-year basis. During the same quarter last year, the firm earned $0.19 EPS.
In other Incyte Corporation news, insider David W. Gryska sold 3,915 shares of the business’s stock in a transaction dated Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP Paula J. Swain sold 20,000 shares of the company’s stock in a transaction dated Thursday, August 31st. The stock was sold at an average price of $140.00, for a total value of $2,800,000.00. Following the sale, the executive vice president now owns 55,067 shares of the company’s stock, valued at approximately $7,709,380. The disclosure for this sale can be found here. Insiders sold 102,062 shares of company stock worth $12,652,893 in the last 90 days. Corporate insiders own 17.70% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. D. Scott Neal Inc. acquired a new position in shares of Incyte Corporation during the 2nd quarter worth about $103,000. Cornerstone Advisors Inc. raised its holdings in Incyte Corporation by 19.6% in the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock valued at $111,000 after acquiring an additional 145 shares in the last quarter. Tower Research Capital LLC TRC raised its holdings in Incyte Corporation by 13.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 108 shares in the last quarter. Exane Asset Management acquired a new position in Incyte Corporation in the 2nd quarter valued at approximately $126,000. Finally, Seven Eight Capital LP acquired a new position in Incyte Corporation in the 2nd quarter valued at approximately $129,000. Institutional investors own 88.57% of the company’s stock.
Incyte Corporation Company Profile
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
What are top analysts saying about Incyte Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Incyte Corporation and related companies.